CohBar Stock Edges Higher As Mitochondria Based Therapeutic Shows Encouraging Action In Early-Stage NASH Trial

CohBar Inc CWBR announced topline results from the Phase 1a/1b study of CB4211 for nonalcoholic steatohepatitis (NASH) and obesity.
The study met its primary endpoint showing that CB4211 was well-tolerated and appeared safe with no serious adverse events.
After four weeks of treatment, CB4211 compared to placebo demonstrated robust and significant reductions in key biomarkers of liver damage, including ALT & AST (higher levels in blood suggest liver damage), glucose levels, and a trend towards lower body weight.
Both the CB4211 and placebo groups had substantial reductions in liver fat content compared to baseline.
The results indicate that CB4211 was well-tolerated and appeared safe with no serious adverse events. The only adverse events occurring in over 10% of subjects receiving CB4211 were transient and generally mild to moderate injection site reactions.
Other than CB4211, the lead program, CohBar, has four preclinical programs. The most advanced is CB5138-3 for idiopathic pulmonary fibrosis (IPF) that is expected to enter human trials in 2022.
As of June 30, CohBar had cash and investments of $13.8 million.
Price Action: CWBR shares are up 61.2% at $2.08 during the premarket session on the last check Wednesday.